Clinical Trial

Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2025 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study was to evaluate the efficacy and safety of tegoprazan and minocycline dual therapy for Helicobacter pylori initial treatment. It is hypothesized that tegoprazan and minocycline dual therapy is non-inferior to bismuth-containing quadruple therapy.Patients diagnosed with H. pylori infection will be randomly divided into one of the above treatments. At week 6 follow-up visits, a urea breath test#rapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-22; most recent amendment 2025-07-01.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-07-01
Trial Details
NCT Number NCT06523764
Lead Sponsor Xijing Hospital of Digestive Diseases
Conditions Helicobacter Pylori Infection Chronic Gastrit
Enrollment 208 participants
Start Date 2024-11-11
Primary Completion 2025-08-01 (estimated)
Study Completion 2025-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-03